These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16278493)

  • 1. The role of buspirone for the treatment of cerebellar ataxia in an older individual.
    Holroyd-Leduc JM; Liu BA; Maki BE; Zecevic A; Herrmann N; Black SE
    Can J Clin Pharmacol; 2005; 12(3):e218-21. PubMed ID: 16278493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].
    Trouillas P; Xie J; Getenet JC; Adeleine P; Nighoghossian N; Honnorat J; Riche G; Derex L
    Rev Neurol (Paris); 1995 Dec; 151(12):708-13. PubMed ID: 8787101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Buspirone in the treatment of cerebellar ataxia].
    Svetel M; Vojvodić N; Filipović SR; Dragasević N; Sternić N; Kostić VS
    Srp Arh Celok Lek; 1999; 127(9-10):312-5. PubMed ID: 10649900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy.
    Heo JH; Lee ST; Chu K; Kim M
    J Neurol Sci; 2008 Aug; 271(1-2):87-90. PubMed ID: 18466925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.
    Trouillas P; Xie J; Adeleine P; Michel D; Vighetto A; Honnorat J; Dumas R; Nighoghossian N; Laurent B
    Arch Neurol; 1997 Jun; 54(6):749-52. PubMed ID: 9193210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia.
    Trouillas P; Xie J; Adeleine P
    Prog Brain Res; 1997; 114():589-99. PubMed ID: 9193169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of buspirone for treatment of cerebellar ataxia. An open-label study.
    Lou JS; Goldfarb L; McShane L; Gatev P; Hallett M
    Arch Neurol; 1995 Oct; 52(10):982-8. PubMed ID: 7575226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of spinocerebellar ataxia with buspirone.
    Assadi M; Campellone JV; Janson CG; Veloski JJ; Schwartzman RJ; Leone P
    J Neurol Sci; 2007 Sep; 260(1-2):143-6. PubMed ID: 17512011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cerebellar ataxia with buspirone: a double-blind study.
    Trouillas P; Xie J; Adeleine P
    Lancet; 1996 Sep; 348(9029):759. PubMed ID: 8806320
    [No Abstract]   [Full Text] [Related]  

  • 11. [Physostigmine in treatment of cerebellar ataxia].
    Aschoff JC; Kailer NA; Walter K
    Nervenarzt; 1996 Apr; 67(4):311-8. PubMed ID: 8684510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design.
    Megna J; O'dell M
    Arch Phys Med Rehabil; 2001 Aug; 82(8):1145-8. PubMed ID: 11494197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open trial of buspirone in the treatment of attention-deficit disorder.
    Niederhofer H
    Hum Psychopharmacol; 2003 Aug; 18(6):489-92. PubMed ID: 12923830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Buspirone chlorhydrate in the treatment of cerebellar ataxia].
    Andrade-Filho AS; Passos-Almeida J; Andrade-Souza VM; Sena-Pereira LR
    Rev Neurol; 2002 Aug 16-31; 35(4):301-5. PubMed ID: 12235556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cerebellar ataxic gait].
    Mochizuki H; Ugawa Y
    Brain Nerve; 2010 Nov; 62(11):1203-10. PubMed ID: 21068457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validating an Ataxia Functional Composite Scale in spinocerebellar ataxia.
    Assadi M; Leone P; Veloski JJ; Schwartzman RJ; Janson CG; Campellone JV
    J Neurol Sci; 2008 May; 268(1-2):136-9. PubMed ID: 18191149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of succimer chelation therapy on postural balance and gait outcomes in children with early exposure to environmental lead.
    Bhattacharya A; Shukla R; Auyang ED; Dietrich KN; Bornschein R
    Neurotoxicology; 2007 May; 28(3):686-95. PubMed ID: 17499360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postural responses to multidirectional stance perturbations in cerebellar ataxia.
    Bakker M; Allum JH; Visser JE; Grüneberg C; van de Warrenburg BP; Kremer BH; Bloem BR
    Exp Neurol; 2006 Nov; 202(1):21-35. PubMed ID: 16808916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treadmill training for ataxic patients: a single-subject experimental design.
    Vaz DV; Schettino Rde C; Rolla de Castro TR; Teixeira VR; Cavalcanti Furtado SR; de Mello Figueiredo E
    Clin Rehabil; 2008 Mar; 22(3):234-41. PubMed ID: 18057087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenge-oriented gait and balance training in sporadic olivopontocerebellar atrophy: a case study.
    Landers M; Adams M; Acosta K; Fox A
    J Neurol Phys Ther; 2009 Sep; 33(3):160-8. PubMed ID: 19809395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.